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Introduction
Smoking tobacco is one of the leading risks to human health (Peto et al. 1992; Doll et al. 2005) . Nicotine is the main neuroactive component of tobacco responsible for physical dependence and addiction. Besides addictive properties, many studies demonstrate positive effects on cognition. Human and animal studies have shown that nicotine improves attention, motor functions, working, and episodic memories (Provost and Woodward 1991; Kumari et al. 2003; Jubelt et al. 2008; Froeliger et al. 2009; Heishman et al. 2010; Mocking et al. 2012) . Nicotine also improves learning, attention, and perception in patients suffering from Alzheimer's disease (Jones et al. 1992; Wilson et al. 1995; White and Levin 1999) . Nicotine withdrawal is often associated with impairments of working and verbal memory and neuroplasticity, while nicotine re-administration restitutes these functions in smoking individuals (Jacobsen et al. 2005; Cole et al. 2010; Grundey et al. 2012a Grundey et al. , 2012b .
The neurophysiological basis for the nicotinic effects on cognition is hypothesized to be its impact on cortical excitability and plasticity, controlled by activation of α 4 β 2 and α 7 nicotinic acetylcholine receptors (nAChRs). These are ligand-gated ion channels (Burnashev 1998; Dajas-Bailador and Wonnacott 2004) , which modulate the permeability of Ca 2+ ions and are centrally involved in plasticity induction (Lisman 2001) . In accordance, animal studies have demonstrated that activation of nicotinic receptors results in long-term potentiation (LTP) facilitation (Matsuyama et al. 2000; Sumikawa 2001a, 2001b; Welsby et al. 2006; Nakauchi et al. 2007 ), reversal of GABAergic inhibition of LTP (Fujii et al. 2000) , as well as longterm depression (LTD) enhancement Sumikawa 2001a, 2001b; Ge and Dani 2005) .
Recently, studies in humans demonstrated that global cholinergic activation increases focally, but abolishes non-focally induced LTP-like plasticity, whereas it preserves and prolongs both focal and non-focal LTD-like plasticity. For nicotine, a similar effect was seen for LTP-like plasticity, but LTD-like plasticity was abolished by this substance in non-smoking healthy humans Thirugnanasambandam et al. 2012) . These results show a partial dissociation of the impact of global cholinergic activation and nicotinic receptor activation on plasticity. Furthermore, the "focusing effect" on LTP-like plasticity might explain a beneficial impact on cognition.
In these studies, focal and non-focal plasticity were induced by transcranial direct current stimulation (tDCS) and paired associative stimulation (PAS), respectively. Both tDCS and PAS are non-invasive brain stimulation techniques inducing longlasting changes of cortical excitability, which are Ca 2+ and NMDA receptor-dependent Paulus 2000, 2001; Stefan et al. 2000 Stefan et al. , 2002 Nitsche, Fricke, et al. 2003; Wolters et al. 2003) . Neuroplastic changes induced by tDCS are non-focal and affect neuronal populations beneath the relatively large stimulation electrodes via subthreshold resting membrane potential modulation (Purpura and McMurtry 1965; Nitsche, Roth, et al. 2007; Nitsche et al. 2008) . In contrast, plasticity induced by PAS is presumed to be focal, synapse-specific, and timing-dependent, affecting only selective neuronal populations. During PAS, a repetitive electric pulse to a peripheral nerve is combined with a suprathreshold transcranial magnetic stimulation (TMS) pulse over the corresponding area of the primary motor cortex. The target group of somatosensory-motor cortical synaptic connections is activated synchronously or asynchronously by combined peripheral and TMS pulses, depending on the interstimulus interval (ISI), resulting in excitatory or inhibitory after-effects (Stefan et al. 2000) . PAS is thought to be closely linked to learning and memory processes, as its mechanism resembles some characteristics of spike-timing-dependent plasticity (Stefan et al. 2002; Wolters et al. 2003; Caporale and Dan 2008) .
Beyond unspecific activation of nicotinic receptors by nicotine, not much is known about the contribution of nicotinic receptor subtypes on neuroplasticity in humans. Given that tDCS and PAS induce calcium-dependent plasticity, it can be speculated that specifically nicotinic receptors with calcium channel properties might be involved. In accordance, in the present study, we aimed to explore the contribution of α 4 β 2 receptors on non-invasive brain stimulation-induced focal and non-focal plasticity in human non-smokers via application of varenicline. Varenicline is an effective smoking cessation agent (Coe et al. 2005) , which is a high-affinity partial agonist to α 4 β 2 and full agonist to α 7 nAChRs (Mihalak et al. 2006) . Varenicline is also suggested to have therapeutic effects in patients suffering from Alzheimer's disease (Kem 2000; Jensen et al. 2005) , schizophrenia, depression during smoking abstinence (Hong et al. 2011; Liu et al. 2011; Shim et al. 2012; Anthenelli et al. 2013) , and patients with ataxia (Zesiewicz et al. 2012) . Studying the impact of varenicline on plasticity might thus not only be suited to explore the physiology of nicotinic receptor activation to a larger extent, but also help to comprehend its impact on clinical symptoms. We hypothesized that effective dosages of the drug should, similar to the effect of nicotine (Thirugnanasambandam et al. 2012) , abolish tDCS-induced non-focal plasticity and preserve PAS-induced focal excitatory plasticity in non-smoking healthy subjects.
Materials and Methods

Subjects
Twenty-five healthy non-smokers aged 24.8 ± 4.4 years (11 males/15 females) were recruited. Two subjects did not finish the experiment. One subject took part in both, the tDCS and PAS parts of the study. All subjects were right-handed according to the Edinburgh handedness inventory (Oldfield 1971) . None of them took any medication, had a history of a neuropsychiatric or medical disease, present pregnancy, or metallic head implants. All volunteers gave written informed consent and were compensated for participation. The investigation was approved by the Ethics Committee of the University of Göttingen and conforms to the principles laid down in the Declaration of Helsinki.
Transcranial Direct Current Stimulation
Twelve subjects aged 24.4 ± 4.7 years (4 males/8 females) participated in the tDCS experiment. Direct current was delivered by a batterydriven constant current stimulator (neuroConn GmbH, Ilmenau, Germany) through a pair of rubber electrodes covered with salinesoaked sponges (5 × 7 cm). The motor cortex electrode was fixed over the area representing the right abductor digiti minimi muscle (ADM) and the return electrode contralaterally above the right supraorbital area. Subjects received 1 mA of either excitability-enhancing anodal tDCS for 13 min or excitability-diminishing cathodal tDCS for 9 min, which induces motor cortex excitability alterations lasting for about 1 h (Nitsche and Paulus 2001; . To achieve a functionally monopolar stimulation over the primary motor cortex, an enlarged return electrode could have been used (Nitsche, Doemkes, et al. 2007 ). We did not use such a large return electrode to keep the experimental design identical to those of former studies of our group (Kuo et al. 2008; Monte-Silva et al. 2009 Thirugnanasambandam et al. 2012) , since the size of the return electrode seems to have no impact on resulting motor cortex plasticity (Nitsche, Doemkes, et al. 2007 ).
Paired Associative Stimulation
Twelve subjects 25 ± 4.4 years (6 males/6 females) participated in the PAS experiment. The peripheral electric pulse over the right ulnar nerve at the level of the wrist at an intensity of 300% of the sensory perceptual threshold was followed by a TMS pulse over the M1 representation of the ADM at ISIs of 10 ms (PAS10) or 25 ms (PAS25) at a frequency of 0.05 Hz. The peripheral electric pulse was delivered by a Digitimer D184 multipulse stimulator (Digitimer, Welwyn Garden City, UK). The TMS pulse was delivered by a Magstim 200 stimulator with an intensity to elicit single-pulse motor evoked potentials (MEPs) with peak-to-peak amplitudes of on average 1 mV. The participants were instructed to silently count the number of pulses they received at their wrist during the whole stimulation duration to guarantee sufficient attention to the procedure, which has been shown to be crucial to obtain the desired after-effects (Stefan et al. 2000 (Stefan et al. , 2004 .
Pharmacological Interventions
Low (0.1 mg), medium (0.3 mg), or high (1.0 mg) dosages of varenicline or 0.5 mg placebo were administered in form of 2-piece gelatin capsules (size 2, 18 mm length, 6.35 mm external diameter) 3 h before the start of the experimental session, allowing the verum drug to induce a maximum plasma level and to produce prominent effects in the central nervous system. One milligram of varenicline is a single oral dosage administered in smokers to support cessation of tobacco consumption (Faessel et al. 2006 (Faessel et al. , 2010 Obach et al. 2006 ).
Monitoring of Motor Cortical Excitability
MEPs were recorded from the right ADM by single-pulse TMS over the corresponding left primary motor cortex, conducted by a Magstim 200 magnetic stimulator (Magstim, Whiteland, Dyfed, UK) with a figure-ofeight magnetic coil (diameter of one winding-70 mm; peak magnetic field-2.2 T). The coil was held tangentially to the skull, with the handle pointing backwards and laterally at 45°from the midline. The hotspot was defined as the optimal coil placement, where the TMS pulse resulted consistently in the largest MEPs of the contralateral ADM. Surface MEPs were recorded from the right ADM with Ag-AgCl electrodes in a belly-tendon montage. The signals were amplified, band-pass filtered (2 Hz-2 kHz, sampling rate, 5 kHz), digitized with a micro-1401 AD converter (Cambridge Electronic Design, Cambridge, UK), controlled by the Signal Software (Cambridge Electronic Design, v. 2.13), and stored for offline analysis.
Experimental Procedures
A unique sequence of experimental sessions was randomly generated individually for each subject, which did not match any previously generated one for other subjects. The participants were seated in a comfortable chair with head and arm rests. In the beginning, the hotspot was identified by TMS and then the stimulation intensity was adjusted to elicit single-pulse MEPs with peak-to-peak amplitudes of on average 1 mV. Then, 25 MEPs were recorded for the determination of first baseline. After baseline recording, varenicline or placebo medication was administered. Three hours after intake of medication, a second baseline was recorded to monitor for a possible impact of the drug alone on cortical excitability (baseline 2), and TMS intensity was adjusted, if necessary (baseline 3). After that procedure, the respective plasticity induction protocol was administered (cathodal tDCS, anodal tDCS, PAS10 or PAS25) and 25 MEPs were recorded at time points of 0, 5, 10, 15, 20, 25, 30, 60, 90 , and 120 min after tDCS. Further TMS measurements were conducted in the evening of the same day (SE), next morning, at approximately 9:00 AM (NM), next noon, at approximately 12:00 PM (NN), and next evening, at approximately 6:00 PM (NE) (Fig. 1) . To keep the surface electromyography electrodes and TMS coil at the same place for later measurements, their positions were marked with a waterproof pen. The minimum period between 2 consecutive experimental sessions for a single subject was 7 days. Subjects were blinded for both, stimulation and medication conditions; the experimenter was blinded for the medication condition.
Analysis and Statistics
The experimenter was unblinded after finishing data collection and analysis. The individual means of 25 MEP amplitudes were calculated at each time point for every subject, and the post-tDCS mean MEP amplitudes were normalized to the respective mean baseline MEP amplitudes (quotient of post-stimulation MEPs vs. pre-stimulation values: baseline 2 or, if TMS intensity had to be adjusted, baseline 3). Then, the grand averages for each time point were calculated. A repeatedmeasures ANOVA was performed on the above-mentioned data separately for tDCS and PAS experiments, using MEP amplitude as the dependent variable and medication, stimulation type and time course as within-subject factors. The Mauchly test of sphericity was performed, and the Greenhouse-Geisser correction applied when necessary. In case of significant results of the ANOVA, exploratory post hoc comparisons were performed using Student's t-tests ( paired samples, twotailed, P < 0.05, not corrected for multiple comparisons) between the MEP amplitudes before and after intervention within one experimental condition and between the single time points (medication vs. placebo) within the same stimulation condition.
To compare main effects of different dosages of varenicline on plasticity, averaged MEPs for the first 30 min after stimulation were calculated for each subject per experimental session and normalized to baseline 2 (or baseline 3, if TMS intensity was adjusted). Then, these averaged MEP values for each dosage condition were compared with the respective placebo condition by Student's t-tests ( paired samples, two-tailed, P < 0.05, not corrected for multiple comparisons).
To exclude differences between baseline values of different conditions, and also between first, second, and third baseline values, the respective values were compared using Student's t-tests ( paired samples, two-tailed, P < 0.05, not corrected for multiple comparisons).
Results
All subjects tolerated the procedure well. Only 5 of them reported slight dizziness, lasting for about 1 h after drug intake, which is a mild side effect of varenicline.
Two participants (1 from tDCS and 1 from PAS experiment) left the study after the first experimental day due to time constraints.
The average baseline MEP values did not significantly differ between groups as revealed by Student's t-tests ( paired samples, two-tailed, P > 0.05). Varenicline alone did not have any impact on cortical excitability at any dosage, as revealed by Student's t tests between first, second, and third baseline values ( paired samples, two-tailed, P > 0.05) ( Table 1) .
Effect of Varenicline on tDCS-Induced Plasticity
The ANOVA revealed significant main effects of Stimulation (F 1 = 117.900; P < 0.001), Medication × Stimulation (F 3 = 5.050; P = 0.005), Stimulation × Time (F 14 = 10.013; P < 0.001), and Medication × Stimulation × Time (F 42 = 2.375; P < 0.001) interactions (for details see Table 2 ).
Post hoc Student's t-tests show that, in the placebo and low-dose varenicline medication conditions, the latter being 10 times lower than a single oral dosage (1 mg) administered in smokers to support cessation of tobacco consumption (Faessel et al. 2010 ), MEPs were significantly enhanced for 60 min after anodal and reduced after cathodal tDCS when compared with respective baseline values. MEPs obtained under low-dose varenicline did not differ from those under placebo medication at any time point. Medium-dose varenicline abolished both Figure 1 . Course of the study. In the beginning of each session, before administration of varenicline or placebo medication, 25 baseline single-pulse MEPs were recorded at an intensity to elicit MEPs with peak-to-peak amplitudes of on average 1 mV. Three hours later, a second baseline was recorded to explore the effect of medication on cortical excitability, and adjusted, if necessary (third baseline). Afterwards, tDCS (cathodal or anodal) or PAS (PAS10 or PAS25) was administered and 25 MEPs were recorded immediately after stimulation and at time points of 5, 10, 15, 20, 25, 30, 60, 90 , and 120 min after plasticity induction. Further TMS measurements were conducted in the evening of the same day (SE), next morning, at approximately 9:00 AM (NM), next noon, at approximately 12:00 PM (NN), and next evening, at approximately 6:00 PM (NE). Note. Shown are the mean MEP amplitudes ± SD and stimulation intensity (percentage of maximum stimulator output, %MSO) mean ± SD of baselines 1, 2, and 3. The intensity of TMS was adjusted to elicit MEPs with peak-to-peak amplitude of approximately 1 mV (baseline 1). A second baseline (baseline 2) was recorded 3 h after varenicline or placebo intake to determine the impact of the drug on cortical excitability and adjusted if necessary (baseline 3). Student's t-tests revealed no significant differences between conditions (P > 0.05).
anodal and cathodal tDCS-induced after-effects. Here, MEP amplitudes did not differ from baseline values at any time point, and MEPs were significantly altered as compared with the respective placebo medication conditions for up to 30 min after tDCS. Under high-dose varenicline, the cathodal tDCS-induced excitability diminution was significant versus baseline until the evening after tDCS, but did not differ significantly from the placebo medication condition. For anodal tDCS, the respective excitability enhancement was initially abolished, and MEPs were significantly smaller than those under placebo medication for the first 10 min after tDCS. However, MEPs were enhanced versus baseline between 25 and 30 min after plasticity induction ( Fig. 2A,B ). For the effects of different dosages of varenicline on tDCSinduced plasticity with regard to the grand average calculated for the first 30 min after intervention, a medium dose of varenicline had a significant abolishing effect on both excitability-enhancing and -diminishing non-focal plasticity, as revealed by respective Student's t-tests (Student's t-test, paired samples, two-tailed, P < 0.01). Furthermore, the anodal tDCS-induced excitability enhancement was abolished by high-dose varenicline (Student's t-test, paired samples, two-tailed, P = 0.02). A low dose of varenicline showed no significant differences from the respective placebo medication conditions (Student's t-test, paired samples, two-tailed, P > 0.05) (Fig. 4) .
Effect of Varenicline on PAS-Induced Plasticity
The ANOVA revealed significant main effects of Stimulation (F 1 = 19.134; P = 0.003), Stimulation × Time (F 14 = 19.064; P < 0.001), and Medication × Stimulation × Time (F 42 = 1.476; P = 0.035) interactions (Table 2) .
Post hoc Student's t-tests show that MEPs were significantly enhanced for about an hour after PAS25 in all medication conditions, and reduced after PAS10 in the placebo and low-dose varenicline conditions, when compared with respective baseline values. Medium and high doses of varenicline abolished PAS10-induced after-effects. Here, MEP amplitudes did not differ from baseline values at any time point, and MEPs were significantly altered when compared with the respective placebo medication conditions for up to 60 min after PAS administration. In all other conditions, MEPs obtained after varenicline administration did not differ from those under placebo medication at any time point (Fig. 3A,B ).
For the effects of different dosages of varenicline on PASinduced plasticity with regard to the grand average calculated for the first 30 min after intervention, medium and high doses of varenicline have a significant abolishing effect on PAS10-induced focal inhibitory plasticity as revealed by the respective Student's t-tests (Student's t-test, paired samples, two-tailed, P < 0.001 and P = 0.01, respectively). The other conditions showed no significant differences from the respective placebo medication conditions (Student's t-test, paired samples, two-tailed, P > 0.05; Fig. 4 ).
Discussion
The results of this study show that activation of nicotinic α 4 β 2 and, possibly, α 7 receptors has specific and dosage-dependent effects on neuroplasticity in healthy human non-smoking individuals. Low-dosage varenicline did not affect plasticity. In contrast, a medium dose of the drug induced collapse of non-focal, but preserved focal, LTP-like plasticity. Under high dosages of the drug non-focal LTP-like and focal LTD-like plasticity were compromised, whereas non-focal and focal LTP-like effects remained preserved. Preference of focal excitatory plasticity obtained under medium-dosage varenicline is fairly identical to the one of a previous study, which explored the impact of nicotine on tDCS-induced plasticity Thirugnanasambandam et al. 2012) . Therefore, we presume that the focusing effect of nicotine on facilitatory plasticity is at least partially caused by α 4 β 2 receptors. As the MEP amplitudes alone were not affected by any dose of varenicline, a direct influence of the drug on cortical excitability can be ruled out.
Proposed Mechanisms of Action
After-effects of tDCS and PAS are NMDA receptor-and Ca 2+ -dependent (Stefan et al. 2002; Nitsche, Fricke, et al. 2003; Wolters et al. 2003) . Since α 4 β 2 and α 7 nAChRs are ligand-gated ion channels (Burnashev 1998; Dajas-Bailador and Wonnacott 2004) , they might affect LTP and LTD induction by an alteration of membrane permeability to Ca 2+ ions (Lisman 2001) . Indeed, in animal slice experiments, agonists of the respective receptors have a prominent impact on stimulation-induced plasticity. Nicotine has been shown to enhance LTP by postsynaptically activating α 7 nicotinic receptors in the rat dentate gyrus (Welsby et al. 2006) , and facilitates NMDA-dependent LTP induction (Yamazaki et al. 2005; Yamazaki, Jia, Niu, et al. 2006; Yamazaki, Jia, Wong, et al. 2006; Griguoli et al. 2013; Prestori et al. 2013 ). In another study, activation of both α 4 β 2 and α 7 nicotinic receptors was essential for LTP induction (Matsuyama and Matsumoto 2003) . Since activation of nAChRs increased intracellular Ca 2+ in several studies (Chavez-Noriega et al. 1997 , 2000 Khiroug et al. 2003; Karadsheh et al. 2004; Yakel 2005, 2007; Jia et al. 2010 ), this effect is most probably accomplished by calcium concentration alterations.
At first glance, the impact of nicotinic receptor enhancement on plasticity in the present experiment is not completely compatible with the direction of effects obtained in the abovementioned animal experiments, especially with regard to LTD induction. However, the key for understanding the results might be the non-linear impact of calcium on plasticity. Whereas low intraneuronal calcium enhancement induces LTD, high concentrations induce LTP. In between, a "no man's land" does exist, in which no plasticity results, and very high calcium concentrations might also prevent plasticity because of activation of hyperpolarizing potassium channels (Lisman 2001; Misonou et al. 2004) . Therefore, whereas both strains of experiments stress the role of nicotine receptors for plasticity, the reason for differently directed results of animal and human experiments might be different amounts of calcium influx caused by the respective receptor agonists, and plasticity induction procedures. The reason that low-dosage varenicline had no significant effect on plasticity is most probably that this dosage did not suffice to activate nicotinic receptors to an amount at which these induce relevant intraneuronal calcium concentration alterations. The plasticity-abolishing effects of the medium and high dosages of the drug with regard to excitability-diminishing plasticity and tDCS-induced facilitatory plasticity go in line with the results of previous studies (Grundey et al. 2012a (Grundey et al. , 2012b Thirugnanasambandam et al. 2012) , where global nicotinic receptor activation resulted in abolishment of these kinds of plasticity. Therefore, it is plausible that at least a part of the impact of nicotine on plasticity is driven by α 4 β 2 and α 7 receptors. As varenicline is a full agonist of α 7 and potent partial agonist of α 4 β 2 receptors, with a far greater affinity (4000-to 5000-fold) to α 4 β 2 when compared with α 7 receptors (Avalos et al. 2002; Jensen et al. 2005; Mihalak et al. 2006; Rollema et al. 2010) , the α 4 β 2 receptor might have a larger relevance for the results. Due to the above-mentioned calcium hypothesis, the most probable explanation for the abolishment of LTD-like plasticity by the medium dosage of the drug is that here nicotinic receptor activation drove calcium concentrations in the respective "no man's lands". For the abolishment of the non-focal LTP-like plasticity induced by anodal tDCS under high-dosage varenicline, the same mechanism might apply. In contrast, the PAS25-induced excitability enhancement was not affected by any dose of varenicline. This can be explained by differences between the stimulation-inducing protocols. Neuroplastic changes via tDCS are achieved by long-lasting, tonic depolarization of large neuronal populations and activation of voltage-dependent Ca 2+ -channels, whereas PAS only affects small groups of neurons and causes short-lasting depolarizations. Therefore, the amount of intracellular calcium increase may be smaller with regard to PAS when compared with tDCS and not sufficient to induce significant changes in neuroplasticity (Thirugnanasambandam et al. 2012) .
This mechanism does, however, not explain the reestablishment of cathodal tDCS-induced LTD-like plasticity under the high dosage of the drug. Here, it could be speculated that an antagonistic effect of varenicline on the respective nicotinic receptor, which takes place for higher dosages of the drug, resulted in reduced calcium influx, and thus a restitution of plasticity. These mechanistic explanations are, however, hypothetical at present and should be explored more directly in future studies in humans and animal models.
For the overall pattern of experimental results, varenicline applied in medium and high doses results in a focusing effect on facilitatory neuroplasticity. While preserving focal plasticity, it exerts its effect mainly by first abolishing both non-focal facilitatory and focal inhibitory plasticity, similar to global nicotinic and cholinergic system activation Thirugnanasambandam et al. 2012) . Such a focusing effect might be beneficial for task performance via enhancing the signal-to-noise ratio by selectively strengthening specific task-related synapses and suppressing irrelevant, non-specific neuronal activity. This can explain the positive nicotinic effect on cognitive functions (attention, working, and episodic memory), where a stable processing of information is essential (Provost and Woodward 1991; Kumari et al. 2003; Jubelt et al. 2008; Froeliger et al. 2009; Heishman et al. 2010; Mocking et al. 2012) . At the highest dose of 1-mg cathodal inhibition is restored again, which may further contribute to the signal-to-noise ratio. When using a noisy random dot paradigm, subjects under cathodal stimulation were superior in detecting coherent motion (Antal et al. 2004 ). LTD has also been identified as an important mechanism involved in specific forms of learning and memory In the placebo and 0.1-mg varenicline medication conditions, cortical excitability was significantly reduced up to 60 min after PAS10. 0.3 and 1.0 mg varenicline abolished the above-mentioned excitability diminution. Error bars indicate SEM. Filled symbols indicate significant differences of post-stimulation MEP amplitudes from respective baseline values; asterisks indicate significant differences between the drug and placebo medication conditions at the same time points (Student's t-test, two tailed, paired samples, P < 0.05). (Bear 1999; Manahan-Vaughan 2007, 2008; Griffiths et al. 2008; Collingridge et al. 2010) . It might be speculated that abolishment of certain forms LTD-like plasticity by high and medium doses of varenicline can lead to impairments of LTDdependent forms of cognitive processes, but this has been rarely reported (Levin et al. 2006) . In these cases, re-establishment of non-focal LTD-like plasticity under high-dose varenicline could also contribute to a positive nicotinic effect on LTD-dependent forms of learning and memory formation. Further behavioral experiments should be designed to explore this hypothesis.
General Remarks
This study demonstrates that varenicline has a prominent impact on neuroplasticity in non-smoking humans, which is similar to that of nicotine application. As mentioned above, varenicline has also been explored for therapeutic application in patients with neuropsychiatric diseases (Kem 2000; Jensen et al. 2005; Mihalak et al. 2006; Hong et al. 2011; Liu et al. 2011; Shim et al. 2012; Zesiewicz et al. 2012; Anthenelli et al. 2013) . It might be speculated that the impact of the drug on neuroplasticity is involved in the respective clinical effects. From this perspective, it will be important to directly correlate the physiological results of our study with the effect of nicotinic receptor activation (α 4 β 2 and possibly α 7 too) on cognition and clinical symptoms in future studies.
As several recently published studies demonstrate age-related changes of plasticity, the results of the study conducted in a group of healthy young subjects might be substantially different from those of older adults. The effect size of PAS-induced plasticity linearly declines across the lifespan (Muller-Dahlhaus et al. 2008; Tecchio et al. 2008) . Similar results on LTD-like plasticity have been demonstrated using continuous theta burst stimulation and repetitive TMS (Todd et al. 2010; Freitas et al. 2011) . Motor learning and motor performance have also been shown to decline with age (Rogasch et al. 2009; Cirillo et al. 2010 Cirillo et al. , 2011 . Moreover, decline in the density of nicotinic receptors with aging have been demonstrated (Schroder et al. 1991) . Therefore, the impact of varenicline on cortical plasticity specifically in older adults should be studied in future experiments.
It has to be taken into account that the results of this study show the impact of only a single-dose varenicline on neuroplasticity. The effect of varenicline after chronic administration on neuroplasticity might be qualitatively different from that after an acute dose. Most of the studies with acute and/or chronic administration of nicotine in animal or human trials report a positive impact on cognitive functions (Rezvani and Levin 2001; Levin et al. 2006) . However, chronic exposure to nicotine can cause upregulation (Wonnacott 1990; Buisson and Bertrand 2001; Mugnaini et al. 2002; Parker et al. 2004) , and desensitization of nAChRs (Hsu et al. 1996; Fenster et al. 1997 Fenster et al. , 1999 , increase in brain-derived neurotrophic factor (BDNF) levels (Kenny et al. 2000) , as well as affect dopaminergic (Pietila and Ahtee 2000; Rahman et al. 2004; Tan et al. 2009 ) and serotoninergic (Awtry and Werling 2003; Semba and Wakuta 2008) systems. Additionally, single-and double-pulse TMS protocols, such as cortical silent period, short-latency afferent inhibition (SAI) and intracortical facilitation (ICF) are affected in smokers and shifted toward cortical excitability diminution, compared with non-smoking individuals, especially under nicotine withdrawal , which suggests an involvement of muscarinic acetylcholine and possibly GABA B , and NMDA receptors (Inghilleri et al. 1996; Ziemann et al. 1996a Ziemann et al. , 1996b Siebner et al. 1998; Di Lazzaro et al. 2000) . This leads to an assumption that chronic administration of nicotine can result in complex changes of plasticity. Indeed, in a group of nicotine-dependent human subjects, nicotine withdrawal resulted in a complete abolishment of tDCS-and PAS-induced facilitatory plasticity, which was restored under nicotine (Grundey et al. 2012a (Grundey et al. , 2012b , whereas in a nonsmoking control group, nicotine had the above-mentioned focusing effect on plasticity (Thirugnanasambandam et al. 2012 ). The respective mechanisms responsible for these effects should be addressed in future studies.
Since a recent study has shown that verbal and working memory functions are reduced in smoking individuals after nicotine withdrawal and restituted by nicotine re-administration (Cole et al. 2010; Grundey et al. 2012a Grundey et al. , 2012b , and varenicline has similar effects on working memory performance in nicotine abstinence (Patterson et al. 2009; Loughead et al. 2010) . It might be interesting to explore if varenicline has similar restituting effects on plasticity, as shown for cognitive processes, in these individuals.
Limiting Conditions
A possible limitation to our study is that varenicline is an agonist with moderate affinity to 5-HT3 serotonin receptors (Lummis et al. 2011) . 5-HT3 receptors have a facilitatory impact on plasticity (Normann et al. 2007; Nitsche et al. 2009; Batsikadze et al. 2013) . However, concentrations of therapeutic unbound varenicline in the brain are insufficient for activation of these receptors (Rollema et al. 2011) . Moreover, in a recently conducted study, the serotonin reuptake inhibitor citalopram enhanced tDCS-induced LTP-like plasticity, and converted LTD-like plasticity into facilitation ). These results are qualitatively different to those obtained in the present study. Varenicline has also an impact on D2/3 dopamine receptor binding and availability in rats (Crunelle et al. 2009 (Crunelle et al. , 2011 (Crunelle et al. , 2012 and GABAergic synaptic transmission (DuBois et al. 2013 ), which have a major impact on stimulation-induced plasticity. It should be noted that, also for these transmitters and receptors, pharmacological modulations resulted in effects which clearly differ from those obtained under varenicline Kuo et al. 2008; Monte-Silva et al. 2009 . Nevertheless, in order to explore the complex interplay of neuromodulatory systems on nicotine-modulated plasticity, future studies should use approaches combining pharmacological interventions with neuroimaging.
It should also be mentioned that the participants were not tested for BDNF and serotonin transporter gene (5-HTTLPR) polymorphisms. Global nicotine and serotonin enhancement has shown to affect BDNF (Nibuya et al. 1995; Kenny et al. 2000; Martinowich and Lu 2008; Andresen et al. 2009 ), BDNF levels also have shown to be significantly lower in smokers than those of non-smoking controls, which is assumed to be caused by long-term nicotine exposure (Bhang et al. 2010; Umene-Nakano et al. 2010) ; however, BDNF levels in smokers did not change significantly after 8-week varenicline treatment (Umene-Nakano et al. 2010). Since non-invasive brain stimulation-induced plasticity is affected by BDNF (Cheeran et al. 2008; Antal et al. 2010; Fritsch et al. 2010) , the complex interaction between the above-mentioned factors should be explored in future studies.
Another limitation is that the specific neurophysiological mechanisms underlying the nicotinic impact on various corticospinal and intracortical excitability parameters were not investigated. We did not perform these measures in the present study, because this would have made it impossible to explore the detailed time course of plasticity. However, it would be important to explore the effect of varenicline on cholinergic activity, for example, by monitoring SAI and on GABAergic and glutamatergic transmission by measuring short-latency intracortical inhibition and ICF (Ziemann et al. 1996a (Ziemann et al. , 1996b Di Lazzaro et al. 2002 Paulus et al. 2008) , to unravel the physiological background of the respective effects.
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